Immunotherapy in SCLC: Challenges and Opportunities of Rapidly Evolving Treatments

Get up to date on optimal use of immunotherapy in the care of your patients with small-cell lung cancer with an interactive on-demand Webcast and downloadable slides from a live Webinar along with a podcast featuring expert answers to frequently asked questions.

Share

Program Content

Activities

FAQ: Immunotherapy in SCLC
Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 27, 2020

Expires: August 26, 2021

View Activity

Activities

Immunotherapy in SCLC
Keeping Pace With the Evolving Treatment Landscape of Immunotherapy in SCLC
Congratulations: You achieved a completion on 04/09/2022
View Activity

Activities

Frontline IO for SCLC
Immune Checkpoint Inhibitor Therapy in the Clinical Management of Newly Diagnosed SCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2020

Expires: July 08, 2021

View Activity
IO for Pretreated SCLC
Immune Checkpoint Inhibitor Therapy in the Clinical Management of Pretreated ES-SCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 09, 2020

Expires: July 08, 2021

View Activity
<i>EP:</i> IO for SCLC
ExpressPoints: Immunotherapy in SCLC: Challenges and Opportunities of Rapidly Evolving Treatments
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2020

Expires: July 14, 2021

View Activity

Faculty

cover img faculity

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.